Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akeso, Inc. has announced a new clinical study titled ‘A Single Arm, Multi-center, Phase II Study of AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC) Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment.’ The study aims to evaluate the efficacy of AK112 in treating NSCLC patients who have not responded to previous TKI therapies, highlighting its potential significance in advancing cancer treatment options.
The intervention being tested is AK112, a drug designed to be administered as a monotherapy. Its purpose is to provide a new treatment avenue for patients with specific genomic alterations in non-squamous NSCLC who have exhausted other options.
This is an interventional study with a single-group assignment. There is no allocation or masking involved, and the primary purpose is treatment-focused. This straightforward design allows for a clear assessment of AK112’s impact on the targeted patient group.
The study is not yet recruiting, with the initial submission date set for August 14, 2025, and the last update on September 3, 2025. These dates are crucial as they mark the timeline for potential recruitment and subsequent data collection phases.
The announcement of this study could influence Akeso’s stock performance positively, as successful outcomes may enhance the company’s position in the oncology market. Investors will likely monitor this development closely, especially considering the competitive landscape in cancer therapeutics.
The study is ongoing, with further details available on the ClinicalTrials portal.